Form 4 for PHAT Phathom Pharmaceuticals, Inc.
Accepted 2024-01-22 00:00:00 ET · period of report 2024-01-18 · accession 0001209191-24-002021 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-22 | 2024-01-19 | PHAT | Henderson Molly | CFO, CBO | S - Sale | $7.75 | -6,307 | 98.7K | -6% | -$48.9K |
| D | 2024-01-22 | 2024-01-18 | PHAT | Henderson Molly | CFO, CBO | A - Grant | $0.00 | +120.0K | 120.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-19 | S | D | 6,307 | $7.75 | 98,698 | D | — | — | (F1) Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. (F2) Includes 1,944 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2024. |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-01-18 | A | A | 120,000 | $0.00 | 120,000 | D | $7.60 · — to 2034-01-17 | 120,000 Common Stock | (F3) The stock option will vest with respect to 25% of the shares of common stock on January 18, 2025, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. |